U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
The FDA has approved Revolution Medicines' RASONQUE (daraxonrasib) as the first broad RAS-targeted medicine for metastatic pancreatic cancer. The approval opens a new drug class in one of oncology's hardest-to-treat cancers and gives Revolution Medicines its first commercial product.
STOCK PHOTO · TREV W. ADAMSThe story
Revolution Medicines announced that the U.S. Food and Drug Administration has granted approval for RASONQUE (daraxonrasib), described as the first broad RAS-targeted medicine cleared for metastatic pancreatic cancer.
The approval directly concerns Revolution Medicines, a clinical-stage-turned-commercial biotech that has built its pipeline around RAS-pathway inhibitors, a target long considered difficult to drug. Pancreatic cancer, particularly metastatic disease, carries poor survival rates and limited treatment options, and RAS mutations are present in a large share of pancreatic tumors, making a broad RAS-targeted approach potentially applicable to a wide patient population rather than a narrow genetically-defined subset.
Key factors to monitor include the company's commercial launch plans, pricing strategy, payer coverage decisions, and real-world uptake among oncologists treating metastatic pancreatic cancer. Analysts will also track guidance on peak sales potential and whether the label supports use earlier in treatment lines or in combination regimens.
Our read · Wed, Aug 26
The FDA approval hands Revolution Medicines its first approved product and a first-in-class label in metastatic pancreatic cancer, shifting the near-term narrative for RVMD from clinical-stage pipeline risk to commercial execution risk.
Why. An FDA approval removes binary regulatory risk and converts the story into a commercial-execution question.
Both cases
What could change this view: Without disclosed launch pricing, payer coverage terms, or uptake data, the market reaction could fade quickly if commercialization details disappoint versus the approval headline.
Who reported it · 2
Keep reading
More on RVMD
FDA grants Revolution Medicines breakthrough status for pancreatic drugLatest on the Wire
Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →Latest on the Wire
Anthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by GlobeNewswire, . Who answers for this
2 reports from 2 publishers in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →